+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Thyroid Cancer - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 1074 Pages
  • September 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5174791
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Pipeline Review, H2 2020, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 6, 42, 34, 1, 5, 20, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 2 molecules, respectively.

Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Thyroid Cancer - Overview

Thyroid Cancer - Therapeutics Development

Thyroid Cancer - Therapeutics Assessment

Thyroid Cancer - Companies Involved in Therapeutics Development

Thyroid Cancer - Drug Profiles

Thyroid Cancer - Dormant Projects

Thyroid Cancer - Discontinued Products

Thyroid Cancer - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Thyroid Cancer, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Thyroid Cancer - Pipeline by ABM Therapeutics Inc, H2 2020
  • Thyroid Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2020
  • Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
  • Thyroid Cancer - Pipeline by AffyImmune Therapeutics Inc, H2 2020
  • Thyroid Cancer - Pipeline by Arch Oncology Inc, H2 2020
  • Thyroid Cancer - Pipeline by Aslan Pharmaceuticals Ltd, H2 2020
  • Thyroid Cancer - Pipeline by AstraZeneca Plc, H2 2020
  • Thyroid Cancer - Pipeline by Bayer AG, H2 2020
  • Thyroid Cancer - Pipeline by BeiGene Ltd, H2 2020
  • Thyroid Cancer - Pipeline by Biocon Ltd, H2 2020
  • Thyroid Cancer - Pipeline by BioMed Valley Discoveries Inc, H2 2020
  • Thyroid Cancer - Pipeline by Biovista Inc, H2 2020
  • Thyroid Cancer - Pipeline by Blueprint Medicines Corp, H2 2020
  • Thyroid Cancer - Pipeline by BNOAT Oncology Inc, H2 2020
  • Thyroid Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
  • Thyroid Cancer - Pipeline by Boston Pharmaceuticals Inc, H2 2020
  • Thyroid Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Thyroid Cancer - Dormant Projects, H2 2020
  • Thyroid Cancer - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Thyroid Cancer, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ABM Therapeutics Inc
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories LLC
  • AffyImmune Therapeutics Inc
  • Arch Oncology Inc
  • Aslan Pharmaceuticals Ltd
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd
  • Biocon Ltd
  • BioMed Valley Discoveries Inc
  • Biovista Inc
  • Blueprint Medicines Corp
  • BNOAT Oncology Inc
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • CAS-Lamvac Biotech Co Ltd
  • Cello Therapeutics Inc
  • Centrose LLC
  • Chengdu Jinrui Foundation Biotechnology Co Ltd
  • Codiak BioSciences Inc
  • CSPC Pharmaceutical Group Ltd
  • CytImmune Sciences Inc
  • Cytocom Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Ecrins Therapeutics SAS
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EnGeneIC Ltd
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Genelux Corp
  • Genmab AS
  • Gradalis Inc
  • Helsinn Group
  • Hutchison MediPharma Ltd
  • ImmunityBio Inc
  • ImmunoForge Co Ltd
  • Immunomedics Inc
  • IngenoVax LLC
  • Innovative Cellular Therapeutics Co Ltd
  • Intensity Therapeutics Inc
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Vcare PharmaTech Co Ltd
  • Johnson & Johnson
  • Kemimedi Co Ltd
  • Kitov Pharma Ltd
  • Konruns Pharmaceutical Co Ltd
  • Lotus Pharmaceutical Co Ltd
  • Loxo Oncology Inc
  • MacroGenics Inc
  • MaxiVAX SA
  • Merck & Co Inc
  • Mersana Therapeutics Inc
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Pfizer Inc
  • Plexxikon Inc
  • Plus Therapeutics Inc
  • PRISM Pharma Co Ltd
  • QED Therapeutics Inc
  • Recordati SpA
  • Regeneron Pharmaceuticals Inc
  • Rodos BioTarget GmbH
  • Savoy Pharmaceuticals Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Shouyao Holding Co Ltd
  • Sino Biopharmaceutical Ltd
  • Sotio AS
  • SpringWorks Therapeutics Inc
  • Suzhou SmartNuclide Biopharmaceutical Co Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Synactix Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Trophogen Inc
  • Turning Point Therapeutics Inc
  • Tyme Technologies Inc
  • UBI Pharma Inc
  • UbiVac LLC
  • Vaccinex Inc
  • Vascular Biogenics Ltd
  • Xiangxue Life Sciences
  • Xspray Pharma AB
  • Xynomic Pharmaceuticals Holdings Inc
  • Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd